文献速递炎症性肠病

基线糖皮质激素使用对瑞生珠单抗在中重度活动性克罗恩病患者中的疗效与安全性及无糖皮质激素临床和内镜结局的影响

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-07-25

这项事后分析基于889例中重度活动性克罗恩病患者,其中285例(32.1%)基线时合并使用糖皮质激素。结果显示,瑞生珠单抗600 mg诱导治疗第12周的临床缓解和内镜应答率不受基线糖皮质激素使用影响;维持治疗第52周,瑞生珠单抗180 mg和360 mg组无糖皮质激素临床缓解及内镜应答率均高于安慰剂组。

要点

  • 瑞生珠单抗600 mg诱导治疗第12周疗效不受基线糖皮质激素使用影响。
  • 第52周瑞生珠单抗180 mg和360 mg组无糖皮质激素内镜应答率分别为44.6%和44.7%,高于安慰剂组20.7%。
  • 不良事件发生率在基线是否使用糖皮质激素的患者中总体相似。

核心结论

  • 瑞生珠单抗600 mg诱导治疗疗效独立于合并糖皮质激素使用。
  • 瑞生珠单抗180 mg和360 mg维持治疗第52周可获得较高的无糖皮质激素临床和内镜结局率。

研究设计与样本

  • 此项为维持治疗期事后分析,诱导期12周内患者维持稳定基线糖皮质激素剂量(泼尼松或等效药物最多20 mg/天),维持治疗第0周开始强制减量糖皮质激素。
  • 889例患者随机接受瑞生珠单抗600 mg或安慰剂诱导治疗,其中285例(32.1%)基线时合并使用糖皮质激素。

主要发现

  • 第12周临床缓解率和内镜应答率在瑞生珠单抗600 mg组高于安慰剂组,无论是否合并使用糖皮质激素。
  • 第52周停用糖皮质激素的患者比例:瑞生珠单抗180 mg组66.7%、瑞生珠单抗360 mg组50.0%、(撤药)安慰剂组41.2%。
  • 第52周无糖皮质激素临床缓解率(基于排便频率/腹痛评分):瑞生珠单抗180 mg组42.7%、瑞生珠单抗360 mg组49.8%、(撤药)安慰剂组39.0%,瑞生珠单抗组高于安慰剂组。
  • 第52周无糖皮质激素临床缓解率(基于克罗恩病活动指数):瑞生珠单抗180 mg组51.0%、瑞生珠单抗360 mg组49.5%、(撤药)安慰剂组40.2%,瑞生珠单抗组高于安慰剂组。
  • 第52周无糖皮质激素内镜应答率:瑞生珠单抗180 mg组44.6%、瑞生珠单抗360 mg组44.7%、(撤药)安慰剂组20.7%,瑞生珠单抗组高于安慰剂组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risankizumab is efficacious and well tolerated in adults with moderately to severely active Crohn's disease (CD). AIM: To evaluate the corticosteroid-sparing effect of risankizumab in CD. METHODS: During the 12-week induction period, patients maintained stable baseline corticosteroid doses, up to 20 mg/day prednisone or equivalent. At week 0 of maintenance, a mandatory corticosteroid taper was started. This post hoc analysis evaluated corticosteroid-free clinical and endoscopic outcomes at week 52 of maintenance; safety was also assessed. RESULTS: Of 889 patients randomised to induction with risankizumab 600 mg or placebo, 285 (32.1%) were taking baseline concomitant corticosteroids. Week 12 clinical remission and endoscopic response rates were greater for risankizumab 600 mg versus placebo, regardless of concomitant corticosteroid use. At week 52, 66.7%, 50.0% and 41.2% of patients taking risankizumab 180 mg, risankizumab 360 mg and (withdrawal) placebo, respectively, discontinued corticosteroids. Week 52 corticosteroid-free clinical remission per stool frequency/abdominal pain score (risankizumab 180 mg [42.7%] or 360 mg [49.8%]; [withdrawal] placebo [39.0%]), corticosteroid-free clinical remission per Crohn's Disease Activity Index (risankizumab 180 mg [51.0%] or 360 mg [49.5%]; [withdrawal] placebo [40.2%]), and corticosteroid-free endoscopic response (risankizumab 180 mg [44.6%] or 360 mg [44.7%]; [withdrawal] placebo [20.7%]) rates were greater for risankizumab than placebo. Adverse event rates were generally similar, regardless of baseline corticosteroid use. CONCLUSIONS: Efficacy of risankizumab 600 mg induction therapy was independent of concomitant corticosteroid use. Risankizumab 180 and 360 mg maintenance therapy yielded high rates of corticosteroid-free clinical and endoscopic outcomes at week 52.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Schreiber S, Cross RK, Panaccione R, et al. Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease. Aliment Pharmacol Ther. 2024. PMID: 39054592. doi:10.1111/apt.18184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。